Triazole-containing hybrids with anti-Mycobacterium tuberculosis potential – Part I: 1,2,3-Triazole

References

• 1. Tornheim JA, Dooley KE. The global landscape of tuberculosis therapeutics. Ann. Rev. Med. 70, 105–120 (2019).
  Medline CASGoogle Scholar
• 2. Saleem A, Azher M. The next pandemic – tuberculosis: the oldest disease of mankind rising one more time. Br. J. Med. Pract. 6(1), a615 (2013).
  Google Scholar
• 3. Turner RD. Cough in pulmonary tuberculosis: existing knowledge and general insights. Pulm. Pharmacol. Ther. 55, 89–94 (2019).
  Medline CASGoogle Scholar
• 4. Abdisamadov A, Tursunov O. Ocular tuberculosis epidemiology, clinic features and diagnosis: a brief review. Tuberculosis 124, e101963 (2020).
  MedlineGoogle Scholar
• 5. World Health Organization. Global tuberculosis report 2019. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
  Google Scholar
• 6. Natarajan A, Beena PM, Devnikar AV, Mali S. A systemic review on tuberculosis. Indian J. Tuberculosis 67(3), 295–311 (2020).
  MedlineGoogle Scholar
• 7. Huszar S, Chibale K, Singh V. The quest for the holy grail: new antitubercular chemical entities, targets and strategies. Drug Discov. Today 25(4), 772–780 (2020).
  Medline CASGoogle Scholar
• 8. Mishra R, Krishan S, Siddiqui AN et al. Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: drug repurposing. Tuberculosis 120, e101902 (2020).
  Medline CASGoogle Scholar
• 9. Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect. Dis. 19(8), 903–912 (2019).
  MedlineGoogle Scholar
• 10. Garcia-Basteiro AL, Jenkins HE, Rangaka M. The burden of latent multidrug-resistant tuberculosis. Lancet Infect. Dis. 19(8), 802–803 (2019).
  MedlineGoogle Scholar
• 11. Gatadi S, Nanduri S. New potential drug leads against MDR-MTB: a short review. Bioorg. Chem. 95, e103534 (2020).
  Medline CASGoogle Scholar
• 12. Gawad J, Bonde C. Current affairs, future perspectives of tuberculosis and antitubercular agents. Indian J. Tuberculosis 65(1), 15–22 (2018).
  MedlineGoogle Scholar
• 13. Neto JSS, Zeni G. A decade of advances in the reaction of nitrogen sources and alkynes for the synthesis of triazoles. Coordin. Chem. Rev. 409, e213217 (2020).
  Google Scholar
• 14. Bozorov K, Zhao J, Aisa HA. 1,2,3-triazole-containing hybrids as leads in medicinal chemistry: a recent overview. Bioorg. Med. Chem. 27(16), 3511–3531 (2019).
  Medline CASGoogle Scholar
• 15. Xia LW, Ba MY, Liu W et al. Triazol: a privileged scaffold for proteolysis targeting chimeras. Future Med. Chem. 11(22), 2919–2973 (2019).
  CASGoogle Scholar
• 16. Kacprzak K, Skiera I, Piasecka M, Paryzek Z. Alkaloids and isoprenoids modification by copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition (click chemistry): toward new functions and molecular architectures. Chem Rev. 116, 5689–5743 (2016).
  Medline CASGoogle Scholar
• 17. Johansson JR, Beke-Somfai T, Said SA, Kann N. Ruthenium-catalyzed azide alkyne cycloaddition reaction: scope, mechanism, and applications. Chem. Rev. 116, 14726–14768 (2016).
  Medline CASGoogle Scholar
• 18. Totobenazara J, Burke AJ. New click-chemistry methods for 1,2,3-triazoles synthesis: recent advances and applications. Tetrahedron Lett. 56, 2853–2859 (2015).
  CASGoogle Scholar
• 19. Xu M, Peng Y, Wang SL et al. Triazole derivatives as inhibitors of Alzheimer's disease: current developments and structure-activity relationships. Eur. J. Med. Chem. 180, 656–672 (2019).
  Medline CASGoogle Scholar
• 20. Kaur A, Mann S, Kaur A et al. Multi-target-directed triazole derivatives as promising agents for the treatment of Alzheimer's disease. Bioorg. Chem. 87, 572–584 (2019).
  Medline CASGoogle Scholar
• 21. Xu Z. 1,2,3-triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). Eur. J. Med. Chem. 206, e112686 (2020).
  Medline CASGoogle Scholar
• 22. Zhang B. Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. Eur. J. Med. Chem. 168, 357–372 (2019).
  Medline CASGoogle Scholar
• 23. Xu Z, Zhao SJ, Liu Y. 1,2,3-triazole-containing hybrids as potential anticancer agents: current developments, action mechanisms and structure-activity relationships. Eur. J. Med. Chem. 183, e111700 (2019).
  Medline CASGoogle Scholar
• 24. Farrer NJ, Griffith DM. Exploiting azide-alkyne click chemistry in the synthesis, tracking and targeting of platinum anticancer complexes. Curr. Opin. Chem. Biol. 55, 59–68 (2020).
  Medline CASGoogle Scholar
• 25. Chu XM, Wang C, Wang WL et al. Triazole derivatives and their antiplasmodial and antimalarial activities. Eur. J. Med. Chem. 166, 206–223 (2019).
  Medline CASGoogle Scholar
• 26. Kharb R, Sharma PC, Yar MS. Pharmacological significance of triazole scaffold. J. Enzym. Inhib. Med. Chem. 26(1), 1–21 (2011).
  Medline CASGoogle Scholar
• 27. Zhang S, Xu Z, Gao C et al. Triazole derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 138, 501–513 (2017).
  Medline CASGoogle Scholar
• 28. Bozorov K, Zhao J, Aisa H. 1,2,3-triazole-containing hybrids as leads in medicinal chemistry: a recent overview. Bioorg. Med. Chem. 27(16), 3511–3531 (2019).
  Medline CASGoogle Scholar
• 29. Feng LS, Zheng MJ, Zhao F, Liu D. 1,2,3-triazole hybrids with anti-HIV-1 activity. Arch. Pharm. 354(1), e2000163 (2021).
  Medline CASGoogle Scholar
• 30. Kumar R, Yar MS, Chaturvedi S, Srivastava A. Triazole as pharmaceuticals potentials. Int. J. Pharm. Tech. Res. 5(4), 1844–1869 (2013).
  CASGoogle Scholar
• 31. Feng LS, Xu Z, Chang L et al. Hybrid molecules with potential in vitro antiplasmodial and in vivo antimalarial activity against drug-resistant Plasmodium falciparum. Med. Res. Rev. 40(3), 931–971 (2020).
  Medline CASGoogle Scholar
• 32. Gao F, Huang G, Xiao J. Chalcone hybrids as potential anticancer agents: current development, mechanism of action, and structure-activity relationship. Med. Res. Rev. 40(5), 2049–2084 (2020).
  Medline CASGoogle Scholar
• 33. Dheer D, Singh V, Shankar R. Medicinal attributes of 1,2,3-triazoles: current developments. Bioorg. Chem. 71, 30–54 (2017).
  Medline CASGoogle Scholar
• 34. Thirmurugan P, Matosiuk D, Jozwiak K. Click chemistry for drug development and diverse chemical–biology applications. Chem. Rev. 113(7), 4905–4979 (2013).
  MedlineGoogle Scholar
• 35. Rani A, Singh G, Singh A et al. CuAAC-ensembled 1,2,3-triazole-linked isosteres as pharmacophores in drug discovery: review. RSC Adv. 10, 5610–5635 (2020).
  CASGoogle Scholar
• 36. Bancet A, Raingeval C, Lomberget T et al. Fragment linking strategies for structure-based drug design. J. Med. Chem. 63(20), 11420–11435 (2020).
  Medline CASGoogle Scholar
• 37. Nalla V, Shaikh A, Bapat S et al. Identification of potent chromone embedded [1,2,3]-triazoles as novel anti-tubercular agents. R. Soc. Open Sci. 5, e171750 (2018).
  MedlineGoogle Scholar
• 38. Stanley SA, Kawate T, Iwase N et al. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. PNAS 110(28), 11565–11570 (2013).
  Medline CASGoogle Scholar
• 39. Keri RS, Nagaraja BM, Santos MA. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents. Eur. J. Med. Chem. 100, 257–269 (2015).
  Medline CASGoogle Scholar
• 40. Hu YQ, Xu Z, Zhang S et al. Recent developments of coumarin-containing derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 136, 122–130 (2017).
  Medline CASGoogle Scholar
• 41. Khare SP, Deshmukh TR, Sangshetti JN et al. Design, synthesis and molecular docking studies of novel triazole-chromene conjugates as antitubercular, antioxidant and antifungal agents. ChemistrySelect 3, 13113–13122 (2018).
  CASGoogle Scholar
• 42. Ashok D, Chiranjeevi P, Kumar AV et al. 1,2,3-Triazole-fused spirochromenes as potential anti-tubercular agents: synthesis and biological evaluation. RSC Adv. 8, 16997–17007 (2018).
  CASGoogle Scholar
• 43. Goud GL, Ramesh S, Ashok D et al. Design, synthesis, molecular docking and antimycobacterial evaluation of some novel 1,2,3-triazolyl xanthenones. MedChemComm 8, 559–570 (2017).
  Medline CASGoogle Scholar
• 44. Shaikh MH, Subhedar DD, Shingate BB et al. Synthesis, biological evaluation and molecular docking of novel coumarin incorporated triazoles as antitubercular, antioxidant and antimicrobial agents. Med. Chem. Res. 25, 790–804 (2016).
  CASGoogle Scholar
• 45. Ambekar SP, Mohan CD, Shirahatti A et al. Synthesis of coumarin-benzotriazole hybrids and evaluation of their anti-tubercular activity. Lett. Org. Chem. 15, 23–31 (2018).
  CASGoogle Scholar
• 46. Ashok D, Gundu S, Amate VK et al. Dimers of coumarin-1,2,3-triazole hybrids bearing alkyl spacer: design, microwave-assisted synthesis, molecular docking and evaluation as antimycobacterial and antimicrobial agents. J. Mol. Struct. 1157, 312–321 (2018).
  CASGoogle Scholar
• 47. Danne AB, Choudhari AS, Sarkar D et al. Synthesis and biological evaluation of novel triazole-biscoumarin conjugates as potential antitubercular and anti-oxidant agents. Res. Chem. Intermed. 44, 6283–6310 (2018).
  CASGoogle Scholar
• 48. Viana JO, Monteiro AFM, Filho JMB et al. The azoles in pharmacochemistry: perspectives on the synthesis of new compounds and chemoinformatic contributions. Curr. Pharm. Des. 25(44), 4702–4716 (2019).
  Medline CASGoogle Scholar
• 49. Das R, Asthana GS, Suri KA et al. Recent developments in azole compounds as antitubercular agent. Mini-Rev. Org. Chem. 16(3), 290–306 (2019).
  CASGoogle Scholar
• 50. Keri RS, Chand K, Ramakrishnappa T, Nagaraja BM. Recent progress on pyrazole scaffold-based antimycobacterial agents. Arch. Pharm. 348(5), 299–314 (2015).
  Medline CASGoogle Scholar
• 51. Keri RS, Patil SA, Budagumpi S, Nagaraja BM. Triazole: a promising antitubercular agent. Chem. Biol. Drug Des. 86(4), 410–423 (2015).
  Medline CASGoogle Scholar
• 52. Shinde V, Mahulikar P, Mhaske PC et al. Synthesis and biological evaluation of new 2-aryl-4-((4-aryl-1H−1,2,3-triazol-1-yl)methyl)thiazole derivatives. Res. Chem. Intermed. 44, 1247–1261 (2018).
  CASGoogle Scholar
• 53. Shinde V, Mhaske PC, Singh A et al. Synthesis and biological evaluation of new 4-(4-(1-benzyl-1H−1,2,3-triazol-4-yl)phenyl)-2-phenylthiazole derivatives. J. Heterocycl. Chem. 56, 3093–3111 (2019).
  CASGoogle Scholar
• 54. Shinde V, Mahulikar P, Mhaske PC et al. Synthesis and antimycobacterial evaluation of new 5-(1-benzyl-1H− 1,2,3-triazol-4-yl)-4-methyl-2-arylthiazole derivatives. Med. Chem. Res. 28, 805–819 (2019).
  CASGoogle Scholar
• 55. Karan S, Kashyap VK, Shafi S, Saxena AK. Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme. J. Mol. Model. 23, e241 (2017).
  MedlineGoogle Scholar
• 56. Nayak N, Ramprasad J, Dalimba U et al. Synthesis of new pyrazole-triazole hybrids by click reaction using a green solvent and evaluation of their antitubercular and antibacterial activity. Res. Chem. Intermed. 42, 3721–3741 (2016).
  CASGoogle Scholar
• 57. Naidu KM, Srinivasarao S, Agnieszka N et al. Seeking potent anti-tubercular agents: design, synthesis, antitubercular activity and docking study of various ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives. Bioorg. Med. Chem. Lett. 26, 2245–2250 (2016).
  Medline CASGoogle Scholar
• 58. Ashok D, Gundu S, Aamate VK, Devulapally MG. Conventional andmicrowave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities. Mol. Divers. 22, 769–778 (2018).
  Medline CASGoogle Scholar
• 59. Reddyrajula R, Dalimba UK. Structural modification of zolpidem led to potent antimicrobial activity in imidazo[1,2-a]pyridine/pyrimidine-1,2,3-triazoles. New J. Chem. 43, 16281–16299 (2019).
  CASGoogle Scholar
• 60. Adeniji SE, Uba S, Uzairu A. Geometrical and topological descriptors for activities modeling of some potent inhibitors against Mycobacterium tuberculosis: a genetic functional approach. Egypt. J. Chem. 62(7), 1235–1247 (2019).
  Google Scholar
• 61. Deniji SE, Uba S, Uzairu A. In silico study for evaluating the binding mode and interaction of 1,2,4-triazole and its derivatives as potent inhibitors against Lipoate protein B (LipB). J. King Saud Univers.-Sci. 32, 475–485 (2020).
  Google Scholar
• 62. Deshmukh TR, Khare SP, Krishna VS et al. Synthesis, bioevaluation and molecular docking study of new piperazine and amide linked dimeric 1,2,3-triazoles. Synth. Commun. 50(2), 271–288 (2020).
  CASGoogle Scholar
• 63. Deshmukh TR, Khare SP, Krishna VS et al. Design and synthesis of new aryloxy-linked dimeric 1,2,3-triazoles via click chemistry approach: biological evaluation and molecular docking study. J. Heterocycl. Chem. 56, 2144–2162 (2019).
  CASGoogle Scholar
• 64. Nainwal LM, Tasneem S, Akhtar W et al. Green recipes to quinoline: a review. Eur. J. Med. Chem. 164, 121–170 (2019).
  Medline CASGoogle Scholar
• 65. Villamizar-Mogotocoro AF, Vargas-Méndez LY, Kouznetsov VV. Pyridine and quinoline molecules as crucial protagonists in the never-stopping discovery of new agents against tuberculosis. Eur. J. Pharm. Sci. 151, e105374 (2020).
  Medline CASGoogle Scholar
• 66. Makafe GG, Hussain M, Surineni G et al. Quinoline derivatives kill Mycobacterium tuberculosis by activating glutamate kinase. Cell Chem. Biol. 26(8), 1187–1194 (2019).
  Medline CASGoogle Scholar
• 67. Pham TDM, Ziora ZM, Blaskovich MAT. Quinolone antibiotics. MedChemComm 10(10), 1719–1739 (2019).
  Medline CASGoogle Scholar
• 68. Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann. Pharmacother. 48(1), 107–115 (2014).
  MedlineGoogle Scholar
• 69. Fan YL, Wu JB, Cheng XW et al. Fluoroquinolone derivatives and their anti-tubercular activities. Eur. J. Med. Chem. 146, 554–563 (2018).
  Medline CASGoogle Scholar
• 70. Liu B, Li F, Zhou T et al. Quinoline derivatives with potential activity against multidrug-resistant tuberculosis. J. Heterocyclic Chem. 55(8), 1863–1873 (2018).
  CASGoogle Scholar
• 71. Reddyrajula R, Dalimba U. Quinoline-1,2,3-triazole hybrids: design and synthesis through click reaction, evaluation of anti-tubercular activity, molecular docking and in silico ADME studies. ChemistrySelect 4, 2685–2693 (2019).
  CASGoogle Scholar
• 72. Ramprasad J, Sthalam VK, Thampunuri RLM et al. Synthesis and evaluation of a novel quinoline-triazole analogs for antitubercular properties via molecular hybridization approach. Bioorg. Med. Chem. Lett. 29, e126671 (2019).
  Medline CASGoogle Scholar
• 73. Banu S, Bollu R, Nagarapu L et al. Design, synthesis, and in vitro antitubercular activity of 1,2,3-triazolyl-dihydroquinoline derivatives. Chem. Biol. Drug Des. 92, 1315–1323 (2018).
  Medline CASGoogle Scholar
• 74. Cilliers P, Seldon R, Smit FJ et al. Design, synthesis, and antimycobacterial activity of novel ciprofloxacin derivatives. Chem. Biol. Drug Des. 94, 1518–1536 (2019).
  Medline CASGoogle Scholar
• 75. Hu YQ, Zhang S, Zhao F et al. Isoniazid derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 133, 255–267 (2017).
  Medline CASGoogle Scholar
• 76. Chaudhari KS, Patel HM, Surana SJ. Pyridines: multidrug-resistant tuberculosis (MDR-TB) inhibitors. Indian J. Tuberculosis 64(2), 119–128 (2017).
  MedlineGoogle Scholar
• 77. Badar AD, Sulakhe SM, Muluk MB et al. Synthesis of isoniazid-1,2,3-triazole conjugates: antitubercular, antimicrobial evaluation and molecular docking study. J. Heterocycl. Chem. 57(10), 3544–3557 (2020).
  CASGoogle Scholar
• 78. Patil PS, Kasare SL, Haval NB et al. Novel isoniazid embedded triazole derivatives: synthesis, antitubercular and antimicrobial activity evaluation. Bioorg. Med. Chem. Lett. 30, e127434 (2020).
  Medline CASGoogle Scholar
• 79. Shaikh MH, Subhedar DD, Nawale L et al. Novel benzylidenehydrazide-1,2,3-triazole conjugates as antitubercular agents: Synthesis and molecular docking. Mini-Rev. Med. Chem. 19, 1178–1194 (2019).
  Medline CASGoogle Scholar
• 80. Yan M, Xu L, Wang Y et al. Opportunities and challenges of using five-membered ring compounds as promising antitubercular agents. Drug Dev. Res. 81(4), 402–418 (2020).
  Medline CASGoogle Scholar
• 81. Gholap SS. Pyrrole: an emerging scaffold for construction of valuable therapeutic agents. Eur. J. Med. Chem. 110, 13–31 (2016).
  Medline CASGoogle Scholar
• 82. Surineni G, Yogeeswari P, Sriram D, Kantevari S. Click-based synthesis and antitubercular evaluation of dibenzofuran tethered thiazolyl-1,2,3-triazolyl acetamides. Bioorg. Med. CHem. Lett. 26, 3684–3689 (2016).
  Medline CASGoogle Scholar
• 83. Chirke SS, Krishna JS, Rathod BB et al. Synthesis of triazole derivatives of 9-ethyl-9H-carbazole and dibenzo[b,d]furan and evaluation of their antimycobacterial and immunomodulatory activity. ChemistrySelect 2, 7309–7318 (2017).
  CASGoogle Scholar
• 84. Vartak A, Goins C, Moura VCN et al. Biochemical and microbiological evaluation of N-aryl urea derivatives against mycobacteria and mycobacterial hydrolases. MedChemComm 10, 1197–1204 (2019).
  Medline CASGoogle Scholar
• 85. Devi ML, Reddy PL, Yogeeswari P et al. Design and synthesis of novel triazole linked pyrrole derivatives as potent Mycobacterium tuberculosis inhibitors. Med. Chem. Res. 26, 2985–2999 (2017).
  CASGoogle Scholar
• 86. Pulipati L, Yogeeswari P, Sriram D, Kantevari S. Click-based synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene-1,2,3-triazoles with piperidine, piperazine, morpholine and thiomorpholine appendages. Bioorg. Med. Chem. Lett. 26, 2649–2654 (2016).
  Medline CASGoogle Scholar
• 87. Marvadi SK, Krishna VS, Sriram D, Kantevari S. Synthesis and evaluation of novel substituted 1,2,3-triazolyldihydroquinolines as promising antitubercular agents. Bioorg. Med. Chem. Lett. 29, 529–533 (2019).
  Medline CASGoogle Scholar
• 88. Marvadi SK, Krishna VS, Sinegubova EO et al. 5-Chloro-2-thiophenyl-1,2,3-triazolylmethyldihydroquinolines as dual inhibitors of Mycobacterium tuberculosis and influenza virus: synthesis and evaluation. Bioorg. Med. Chem. Lett. 29, 2664–2669 (2019).
  Medline CASGoogle Scholar
• 89. Reddyrajula R, Dalimba U. The bioisosteric modification of pyrazinamide derivatives led to potent antitubercular agents: synthesis via click approach and molecular docking of pyrazine-1,2,3-triazoles. Bioorg. Med. Chem. Lett. 30, e126846 (2020).
  Medline CASGoogle Scholar
• 90. Shaikh MH, Subhedar DD, Arkile M et al. Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent. Bioorg. Med. Chem. Lett. 26, 561–569 (2016).
  Medline CASGoogle Scholar
• 91. Reddyrajula R, Dalimba U, Kumar SM. Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: design, synthesis, molecular docking and in silico ADME studies. Eur. J. Med. Chem. 168, 263–282 (2019).
  Medline CASGoogle Scholar
• 92. Srinivasarao S, Nandikolla A, Suresh A et al. Discovery of 1,2,3-triazole based quinoxaline-1,4-di-N-oxide derivatives as potential anti-tubercular agents. Bioorg. Chem. 100, e103955 (2020).
  Medline CASGoogle Scholar
• 93. Maddali NK, Viswanath IVK, Murthy YLN et al. Design, synthesis and molecular docking studies of quinazolin-4-ones linked to 1,2,3-triazol hybrids as Mycobacterium tuberculosis H₃₇Rv inhibitors besides antimicrobial activity. Med. Chem. Res. 28, 559–570 (2019).
  CASGoogle Scholar
• 94. Kumar R, Bimal D, Kumar M et al. Synthesis and antitubercular activity of 4,5-disubstituted N¹-(5′-deoxythymidin-5′-yl)-1,2,3-triazoles. ChemistrySelect 5, 8839–8845 (2020).
  CASGoogle Scholar
• 95. Venugopala KN, Rao GBD, Bhandary S et al. Design, synthesis, and characterization of (1-(4-aryl)-1H−1,2,3-triazol-4-yl)methyl, substituted phenyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates against Mycobacterium tuberculosis. Drug Des. Dev. Ther. 10, 2681–2690 (2016).
  Medline CASGoogle Scholar
• 96. Hajlaoui K, Guesmi A, Hamadi NB, Msaddek M. One-pot synthesis of new triazole-sucrose derivatives via click chemistry and evaluation of their antitubercular activity. Heterocycl. Commun. 22(4), 239–242 (2016).
  CASGoogle Scholar
• 97. Abdu-Allah HHM, Youssif BGM, Abdelrarahman NH et al. Synthesis and anti-mycobacterial activity of 4-(4-phenyl-1H−1,2,3-triazol-1-yl)salicylhydrazones: revitalizing an old drug. Arch. Pharm. Res. 40, 168–179 (2017).
  Medline CASGoogle Scholar
• 98. Bua S, Osman SM, Prete SD et al. Click-tailed benzenesulfonamides as potent bacterial carbonic anhydrase inhibitors for targeting Mycobacterium tuberculosis and Vibrio cholera. Bioorg. Chem. 86, 183–186 (2019).
  Medline CASGoogle Scholar
• 99. Sajja Y, Vanguru S, Vulupala HR et al. Design, synthesis and in vitro anti-tuberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,2,3-triazole derivatives. Bioorg. Med. Chem. Lett. 27, 5119–5121 (2017).
  Medline CASGoogle Scholar
• 100. Suresh A, Srinivasarao S, Agnieszka N et al. Design and synthesis of 9H-fluorenone based 1,2,3-triazole analogues as Mycobacterium tuberculosis InhA inhibitors. Chem. Biol. Drug Des. 91, 1078–1086 (2018).
  Medline CASGoogle Scholar
• 101. Danne AB, Choudhari AS, Chakraborty S et al. Triazole-di-indolylmethane conjugates as new antitubercular agents: synthesis, bioevaluation and molecular docking. MedChemComm 9, 1114–1130 (2018).
  Medline CASGoogle Scholar
• 102. Zhao SJ, Lv ZS, Deng JL et al. Design, synthesis, and in vitro anti-mycobacterial activities of 1,2,3-triazole-tetraethylene glycol tethered isatin dimers. J. Heterocycl. Chem. 55, 3006–3010 (2018).
  CASGoogle Scholar
• 103. Iannazzo L, Soroka D, Triboulet S et al. Routes of synthesis of carbapenems for optimizing both the inactivation of L,D-transpeptidase Ldt_Mt1 of Mycobacterium tuberculosis and the stability toward hydrolysis by β-lactamase BlaC. J. Med. Chem. 59, 3427–3438 (2016).
  Medline CASGoogle Scholar
• 104. Phatak PS, Bakale RD, Dhumal ST et al. Synthesis, antitubercular evaluation and molecular docking studies of phthalimide bearing 1,2,3-triazoles. Synth. Commun. 49(6), 2017–2028 (2019).
  CASGoogle Scholar
• 105. Ruysscher DD, Pang L, Mattelaer CA et al. Phenyltriazole-functionalized sulfamate inhibitors targeting tyrosyl- or isoleucyl-tRNA synthetase. Bioorg. Med. Chem. 28, e115580 (2020).
  MedlineGoogle Scholar
• 106. Negi B, Rawat DS. Synthesis, characterization, and antimycobacterial activity of novel thymol-triazole hybrids. Indian J. Heterocycl. Chem. 28, 113–123 (2018).
  CASGoogle Scholar
• 107. Sajja Y, Vanguru S, Jilla L et al. A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 26, 4292–4295 (2016).
  Medline CASGoogle Scholar
• 108. Liu B, Hu G, Tang X et al. 1H−1,2,3-triazole-tethered isatin-coumarin hybrids: design, synthesis and in vitro anti-mycobacterial evaluation. J. Heterocycl. Chem. 55, 775–780 (2018).
  CASGoogle Scholar
• 109. Huang GC, Xu Y, Xu Z et al. Propylene-1H−1,2,3-triazole-4-methylene-tethered isatin-coumarin hybrids: design, synthesis, and in vitro anti-tubercular evaluation. J. Heterocycl. Chem. 55, 830–835 (2018).
  CASGoogle Scholar
• 110. Xu Y, Dang R, Guan J et al. Isatin-(thio)semicarbazide/oxime-1H−1,2,3-triazole-coumarin hybrids: design, synthesis, and in vitro anti-mycobacterial evaluation. J. Heterocycl. Chem. 55, 1069–1073 (2018).
  CASGoogle Scholar
• 111. Jin X, Yang X, Chen X et al. Design, synthesis and in vitro anti-microbial evaluation of ethylene/propylene-1H−1,2,3-triazole-4-methylene-tethered isatin-coumarin hybrids. Curr. Top. Med. Chem. 17, 3213–3218 (2017).
  Medline CASGoogle Scholar
• 112. Srivastava S, Bimal D, Bohra K et al. Synthesis and antimycobacterial activity of 1-(β-D-Ribofuranosyl)-4-coumarinyloxymethyl-/-coumarinyl-1,2,3-triazole. Eur. J. Med. Chem. 150, 268–281 (2018).
  Medline CASGoogle Scholar
• 113. Somagond SM, Kamble RR, Bayannavar PK et al. Click chemistry based regioselective one-pot synthesis of coumarin-3-yl-methyl-1,2,3-triazolyl-1,2,4-triazol-3(4H)-ones as newer potent antitubercular agents. Arch. Pharm. 352(10), e1900013 (2019).
  Medline CASGoogle Scholar
• 114. Khanapurmath N, Kulkarni MV, Joshi SD, Kumar GNA. A click chemistry approach for the synthesis of cyclic ureido tethered coumarinyl and 1-aza coumarinyl 1,2,3-triazoles as inhibitors of Mycobacterium tuberculosis H₃₇Rv and their in silico studies. Bioorg. Med. Chem. 27, e115054 (2019).
  Medline CASGoogle Scholar
• 115. Xu Z, Lv ZS, Song XF, Qiang M. Ciprofloxacin-isatin-1H−1,2,3-triazole hybrids: design, synthesis, and in vitro anti-tubercular activity against M. tuberculosis. J. Heterocycl. Chem. 55, 97–101 (2018).
  CASGoogle Scholar
• 116. Hu YQ, Meng LD, Qiang M, Song XF. Design, synthesis, and in vitro anti-mycobacterial evaluation 1H−1,2,3-triazole-tethered ciprofloxacin and isatin conjugates. J. Heterocycl. Chem. 54, 3725–3729 (2017).
  CASGoogle Scholar
• 117. Chen RX, Zhang H, Ma T et al. Ciprofloxacin-1,2,3-triazole-isatin hybrids tethered via amide: design, synthesis, and in vitro anti-mycobacterial activity evaluation. Bioorg. Med. Chem. Lett. 29, 2635–2637 (2019).
  Medline CASGoogle Scholar
• 118. Xu Z, Song X, Hu Y et al. Design, synthesis and in vitro anti-mycobacterial activities of 8-OMe ciprofloxacin-1H−1,2,3-triazole-isatin-(thio) semicarbazide/oxime hybrids. J. Heterocycl. Chem. 55, 192–198 (2018).
  CASGoogle Scholar
• 119. Xu Z, Song XF, Qiang M, Lv ZS. 1H−1,2,3-triazole-tethered 8-OMe ciprofloxacin and isatin hybrids: design, synthesis and in vitro anti-mycobacterial activities. J. Heterocycl. Chem. 54, 3735–3761 (2017).
  CASGoogle Scholar
• 120. Xu Z, Song XF, Hu YQ et al. Azide-alkyne cycloaddition towards 1H−1,2,3-triazole-tethered gatifloxacin and isatin conjugates: design, synthesis and in vitro anti-mycobacterial evaluation. Eur. J. Med. Chem. 138, 66–71 (2017).
  Medline CASGoogle Scholar
• 121. Xu Z, Zhang S, Song X et al. Design, synthesis and in vitro anti-mycobacterial evaluation of gatifloxacin-1H−1,2,3-triazole-isatin hybrids. Bioorg. Med. Chem. Lett. 27, 3643–3646 (2017).
  Medline CASGoogle Scholar
• 122. Ding Z, Hou P, Liu B. Gatifloxacin-1,2,3-triazole-isatin hybrids and their antimycobacterial activities. Arch. Pharm. 352, e1900135 (2019).
  Medline CASGoogle Scholar
• 123. Xu Z, Song XF, Fan J, Lv ZS. Design, synthesis, and in vitro anti-mycobacterial evaluation of propylene-1H−1,2,3-triazole-4-methylene-tethered (thio)semicarbazone-isatin-moxifloxacin hybrids. J. Heterocycl. Chem. 55, 77–82 (2018).
  CASGoogle Scholar
• 124. Hu YQ, Xu Z, Qiang M, Lv ZS. Design, synthesis and in vitro antimycobacterial activities of isatin-1,2,3-triazole-moxifloxacin hybrids. J. Heterocycl. Chem. 55, 187–191 (2018).
  CASGoogle Scholar
• 125. Hu YQ, Fan J, Song X. Design, synthesis and in vitro anti-mycobacterial activity of propylene-1H−1,2,3-triazole-4-methylene-tethered isatin-moxifloxacin hybrids. J. Heterocycl. Chem. 55, 246–250 (2018).
  CASGoogle Scholar
• 126. Yan X, Lv Z, Wen J et al. Synthesis and in vitro evaluation of novel substituted isatinpropylene-1H−1,2,3-triazole-4-methylene-moxifloxacin hybrids for their anti-mycobacterial activities. Eur. J. Med. Chem. 143, 899–904 (2019).
  Google Scholar
• 127. Jiang Y, Qian A, Li Y. 1H−1,2,3-Triazole tethered isatin-moxifloxacin: Design, synthesis and in vitro anti-mycobacterial evaluation. Arch. Pharm. 352, e1900040 (2019).
  MedlineGoogle Scholar
• 128. Gao F, Chen Z, Ma L et al. Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. Eur. J. Med. Chem. 180, 648–655 (2019).
  Medline CASGoogle Scholar
• 129. Bangalore PK, Vagolu SK, Bollikanda RK et al. Usnic acid enaminone-coupled 1,2,3-triazoles as antibacterial and antitubercular agents. J. Nat. Prod. 83, 26–35 (2020).
  Medline CASGoogle Scholar
• 130. Singh A, Viljoen A, Kremer L, Kumar V. Azide-alkyne cycloaddition en route to 4-aminoquinoline-ferrocenylchalcone conjugates: Synthesis and anti-TB evaluation. Future Med. Chem. 9, 1701–1708 (2017).
  CASGoogle Scholar
• 131. Singh A, Biot C, Viljoen A et al. 1H−1,2,3-triazole-tethered uracil-ferrocene and uracil-ferrocenylchalcone conjugates: synthesis and antitubercular evaluation. Chem. Biol. Drug Des. 89, 856–861 (2017).
  Medline CASGoogle Scholar
• 132. Raju KS, AnkiReddy S, Sabitha G et al. Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents. Bioorg. Med. Chem. Lett. 29, 284–290 (2019).
  MedlineGoogle Scholar